Sidoti Csr Weighs in on Kamada’s Q2 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at Sidoti Csr boosted their Q2 2025 earnings per share (EPS) estimates for shares of Kamada in a report released on Monday, March 3rd. Sidoti Csr analyst J. Sidoti now forecasts that the biotechnology company will earn $0.08 per share for the quarter, up from their previous estimate of $0.07. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. Sidoti Csr also issued estimates for Kamada’s Q3 2025 earnings at $0.08 EPS.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Friday, January 10th.

Kamada Price Performance

Shares of KMDA stock opened at $6.79 on Tuesday. The stock has a market capitalization of $390.29 million, a PE ratio of 24.25, a P/E/G ratio of 0.97 and a beta of 0.99. Kamada has a 1-year low of $4.74 and a 1-year high of $9.15. The business has a 50-day moving average of $7.03 and a 200 day moving average of $6.12.

Institutional Investors Weigh In On Kamada

Several institutional investors and hedge funds have recently bought and sold shares of KMDA. Plato Investment Management Ltd purchased a new stake in Kamada in the 3rd quarter worth approximately $117,000. Public Employees Retirement System of Ohio purchased a new stake in Kamada in the 3rd quarter worth approximately $77,000. JPMorgan Chase & Co. purchased a new stake in Kamada in the 4th quarter worth approximately $67,000. NewEdge Advisors LLC lifted its holdings in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after buying an additional 8,260 shares during the period. Finally, Aristides Capital LLC lifted its holdings in Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the period. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.